Frequency of non-responders of statins in acute coronary syndrome patients
DOI:
https://doi.org/10.55958/jcvd.v18i3.117Keywords:
Acute Coronary Syndrome, Statins, Non-respondersAbstract
BACKGROUND: Acute coronary syndromes (ACS) includes non ST elevation (NSTEMI) or ST elevation myocardial infarction (STEMI) along with unstable angina and is associated with high morbidity and mortality despite advances in treatment. Statins is one of the pharmacological agent in the management of acute coronary syndrome (ACS). After remarkable advances in medical management over many years, a significant proportion of patients still do not respond to Statins.
AIMS & OBJECTIVE: To assess the frequency of non-responders of statins in acute coronary syndrome patients
METHODOLOGY: This cross-sectional study was carried-out at Punjab Institute of Cardiology, Lahore (PIC) from August 10, 2015 to February 10, 2016. Total 325 patients who fulfilled the inclusion criteria were enrolled and counseled about the details of the study. After taking consent, detailed history and examination was recorded. Details were recorded regarding age, gender of the patient. All patients received 10mg of rosuvastatin. Data stratification was done for age, gender and duration of ACS. Chi-square test was used after stratification to check the significance. p-value was taken as significant when less than 0.05.
RESULTS:
The mean age of non-responders was 56.65±8.75 years. Out 325 patients, 81(24.90%) were non-responders. Mean LDL-C at baseline in non-responders was 197.58±19.08 mg/dl and mean LDL-C after statin therapy in non-responders was 154.64±17.77.
CONCLUSION:
There is a significant number of patients with no response to statins. Lipid-lowering statin regimen gives individuals who have recently experienced ACS increased protection against mortality or experiencing serious cardiovascular events. Results show that such patients benefit from early and ongoing LDL cholesterol reduction
References
Huffman JC, Celano CM, Januzzi JL. The relationship between depression, anxiety, and cardiovascular outcomes in patients with acute coronary syndromes. Neuropsychiatric Disease and treatment. 2010;6:123.
Lerner EB, Rea TD, Bobrow BJ, Acker JE, Berg RA, Brooks SC, et al. Emergency Medical Service Dispatch Cardiopulmonary Resuscitation Prearrival Instructions to Improve Survival From Out-of-Hospital Cardiac Arrest A Scientific Statement From the American Heart Association. Circulation. 2012;125(4):648-55.
Stone NJ, Merz CNB, ScM F, Blum FCB, McBride FP, Eckel FRH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. 2013.
Angeli F, Reboldi G, Mazzotta G, Garofoli M, Cerasa MF, Verdecchia P. Statins in acute coronary syndrome: very early initiation and benefits. Therapeutic advances in cardiovascular disease. 2012:1753944712452463.
Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, et al. Statins for acute coronary syndrome. The Cochrane Library. 2012.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
Sacks RM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623-30.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-6.
